Etosuximid

Klassificering: B

Preparat: Ethosuximide Orifarm, Etosuximid 2care4, Etosuximid Abboxia, Etosuximid Ebb, Etosuximid Medartuum, Etosuximid Paranova, Petnidan, Suxinutin, Suxinutin®, Zarondan, Zarontin

ATC kod: N03AD01

Substanser: etosuximid

Sammanfattning

Det saknas kontrollerade studier om skillnader mellan könen avseende effekt och säkerhet för etosuximid. Kvinnor har lägre clearance än män, en skillnad som varierar i grad beroende på dos.

Additional information

Pharmacokinetics and dosing

One study in patients treated with ethosuximide (20 boys/men, 26 girls/women; age 1.5-38 years) showed that plasma concentration increased more rapidly, relative to dose, in girls/women than in boys/men [1]. Another study in young adults (12 men, 21 women), with half of the women on oral contraceptives, revealed a 27% lower clearance in women in general and no difference associated with use of oral contraceptives [2]. No sex differentiation in dosing has been recommended by the pharmaceutical company [3].

Effects

No studies with a clinically relevant sex analysis regarding the effects of ethosuximide have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of ethosuximide have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Försäljning på recept

Fler kvinnor än män hämtade ut oral lösning innehållande etosuximid (ATC-kod N03AD01) på recept i Sverige år 2019, totalt 393 flickor/kvinnor och 215 pojkar/män [4].

Uppdaterat: 2020-03-18

Litteratursökningsdatum: 2019-10-15

Referenser

Smith GA, McKauge L, Dubetz D, Tyrer JH, Eadie MJ. Factors influencing plasma concentrations of ethosuximide. Clin Pharmacokinet. 1979;4:38-52. PubMed
Bachmann KA, Schwartz J, Jauregui L, Sullivan TJ, Martin M. Use of three probes to assess the influence of sex on hepatic drug metabolism. Pharmacology. 1987;35:88-93. PubMed
Suxinutin (etosuximid). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2019-03-30, cited 2019-10-15].
Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.] länk

Författare: Linnéa Karlsson Lind

Faktagranskat av: Mia von Euler, Carl-Olav Stiller

Godkänt av: Karin Schenck-Gustafsson